CatalystMarker
← board

SNYR

distress 10/10 · high distress / dilution risk
$0.18-1%today-95% from 52w high
synergychc.com28 employeesFounded 2010Windham, MEMedical Distribution
Revenue
pre-revenue
Liquidity
$0M
Runway
0.1 yrs
Shares 1y
+58%

Price & events

-90.5% over 6M
$0.18$1.11$2.04Jan 26Apr 26Jul 26116.2Mdilution: EFFECT shelf_effective (2026-05-22)dilution: S-1 shelf_registration (2026-05-15)financing: 8-K material_agreement (2026-05-11)financing: 8-K private_placement (2026-03-25)rating: Ascendiant Capital: Buy (2026-06-10)rating: Ascendiant Capital: Buy (2026-04-14)rating: Ascendiant Capital: Buy (2026-02-02)
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
-7.2%
1W
-12.6%
1M
-54.8%
3M
-90.3%
6M
-95.1%
1Y
2Y
5Y
-98.0%
All

Overview

Market Cap
$2.70M
Enterprise Value
$27.42M
Volume
31.20K
52 Week Range
$0.18 – $3.97
Total Shares
14.90M
Float Shares
8.17M
Short %
1.97%
% Held by Insiders
47.98%
% Held by Institutions
8.61%
RVOL
0.09x
Beta
0.61

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 4

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 14,899,883 · 2 offerings/1y · 1 PIPEs
  • 2026-05-22EFFECTshelf_effective
  • 2026-05-15S-1shelf_registration
  • 2026-05-118-Kmaterial_agreement
  • 2026-03-258-Kprivate_placement
  • 2025-12-09424B5offering
  • 2025-12-09EFFECTshelf_effective
  • 2025-11-26S-3shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2026-06-10Ascendiant CapitalBuy
  • 2026-04-14Ascendiant CapitalBuy
  • 2026-02-02Ascendiant CapitalBuy
  • 2025-11-14Roth CapitalBuy
  • 2025-01-21Roth MKMBuy

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.